·. O. Olén

Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease

J. Halfvarson, V. Bergqvist, J. Ludvigsson, 2024, Digestive diseases and sciences.